Asensus Surgical, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-11-04: Form 8-K; Period of report 2021-11-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2021-10-28: Form 8-K; Period of report 2021-10-27; Description 8.01 Other Events; Details 8.01.
- 2021-10-04: Form 8-K; Period of report 2021-10-04; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2021-09-27: Form 8-K; Period of report 2021-09-27; Description 8.01 Other Events; Details 8.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-11-04 | 8-K | 2021-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2021, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for its third quarter ended September 30, 2021. | transe20211103_8k.htm |
| 2021-10-28 | 8-K | 2021-10-27 | 8.01 Other Events | 8.01 On October 27, 2021, the Board of Directors (the “Board”) of Asensus Surgical, Inc. (the “Company”) approved David Milne, a current director of the Company, to the role of independent Chair of the Board. | transe20211026_8k.htm |
| 2021-10-04 | 8-K | 2021-10-04 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On October 4, 2021, Asensus Surgical, Inc. (the “Company”) disclosed that Paul LaViolette, currently the independent Chair of the Board and a director of the Company had informed the Company that he would leave the Board of Directors (the “Board”) before the end of 2021. | transe20211004_8k.htm |
| 2021-09-27 | 8-K | 2021-09-27 | 8.01 Other Events | 8.01 On September 27, 2021, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance® Robotic Surgery program following the purchase of a Senhance Surgical System. | transe20210927_8k.htm |
| 2021-09-01 | 8-K | 2021-09-01 | 8.01 Other Events | 8.01 On September 1, 2021, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it has received 510(k) clearance from the FDA for an expansion of machine vision capabilities on the previously cleared Intelligent Surgical Unit™ (ISU™). | transe20210901_8k.htm |
| 2021-08-06 | 8-K | 2021-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2021, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for its second quarter ended June 30, 2021. | transe20210805_8k.htm |
| 2021-07-26 | 8-K | 2021-07-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On July 22, 2021, the Board of Directors (the “Board”) of Asensus Surgical, Inc. (the “Company”) increased the size of the Board from seven members to nine members and appointed Kevin Hobert and Elizabeth Kwo, MD to the Board, effective immediately, to fill such vacancies. | transe20210723_8k.htm |
| 2021-07-23 | 8-K | 2021-07-22 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On July 22, 2021, at the 2021 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of Asensus Surgical, Inc. (the “Company”) voted to approve, among other things, the Company’s Amended and Restated Incentive Compensation Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. 5.07 On July 22, 2021, the Company held its 2021 Annual Meeting of Stockholders. | transe20210722_8k.htm |
| 2021-07-15 | 8-K | 2021-07-15 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 On July 15, 2021, Asensus Surgical, Inc. (the “Company”) reported that its Board of Directors had approved an amendment and restatement of the Company’s Amended and Restated Bylaws (the “Bylaws”) to change the quorum for stockholder meetings to equal one-third (33.33%) of the shares issued and outstanding and entitled to vote on the matters at the meeting. | transe20210715_8k.htm |
| 2021-06-03 | 8-K | 2021-06-03 | 8.01 Other Events | 8.01 On June 3, 2021, the 2021 Annual Meeting of Stockholders (the “Annual Meeting”) of Asensus Surgical, Inc. (the “Company”), was adjourned until June 29, 2021, at 11:00 a.m. | transe20210603_8k.htm |
| 2021-05-19 | 8-K | 2021-05-19 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | transe20210518_8k.htm |
| 2021-05-13 | 8-K | 2021-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2021, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2021. | transe20210511_8k.htm |
| 2021-04-30 | 8-K | 2021-04-28 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | transe20210430_8k.htm |
| 2021-03-12 | 8-K | 2021-03-11 | 2.02 Results of Operations and Financial Condition | 2.02 On March 11, 2021, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2020. | transe20210311_8k.htm |
| 2021-03-03 | 8-K | 2021-03-03 | 8.01 Other Events | 8.01 On March 3, 2021, Asensus Surgical, Inc., a Delaware corporation, issued a press release to announce that it had received an additional FDA clearance for the Senhance® Surgical System which allows for indication expansion in general surgery in the United States. | transe20210303_8k.htm |
| 2021-02-25 | 8-K | 2021-02-23 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year | 5.03 The Company’s CUSIP numbers for its common stock, Series C Warrants and Series D Warrants have changed as a result of the corporate name change. | transe20210223_8k.htm |
| 2021-02-23 | 8-K | 2021-02-23 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On February 23, 2021, TransEnterix, Inc., a Delaware corporation (the “Company”) is holding an Investor Day conference. 8.01 On February 23, 2021, the Company also issued a press release announcing its name change, effective February 23, 2021, and a change of its trading symbol to ASXC, to be effective on March 5, 2021. | transe20210222_8k.htm |
| 2021-02-12 | 8-K | 2021-02-08 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On February 8, 2021, the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”) of TransEnterix, Inc. (the “Company”) approved the 2020 incentive bonus, retention bonuses and compensation changes for 2021 for the executive officers of the Company. | transe20210211_8k.htm |
| 2021-01-28 | 8-K | 2021-01-26 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 The Company issued press releases on January 26, 2021, announcing the pricing of the offering and the increase in the size of the offering. | transe20210127_8k.htm |
| 2021-01-19 | 8-K | 2021-01-19 | 8.01 Other Events | 8.01 On January 19, 2021, TransEnterix, Inc., a Delaware corporation, issued a press release to announce that it had received CE Mark approval for the Intelligent Surgical Unit™ that enables vision capabilities on the Senhance® Surgical System. | transe20210119_8k.htm |
| 2021-01-14 | 8-K | 2021-01-12 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 The Company issued a press release on January 12, 2021, announcing the pricing of the Offering and the commitment to sell the Shares. | transe20210112_8k.htm |
| 2021-01-06 | 8-K | 2021-01-06 | 8.01 Other Events | 8.01 On January 6, 2021, TransEnterix, Inc., a Delaware corporation (the “Company”), issued a press release announcing an update with preliminary financial results for the fourth quarter and full year ended December 31, 2020. | transe20210105_8k.htm |